CLK3 Activators
CLK3 activators encompass a diverse range of chemical compounds that indirectly enhance the functional activity of CLK3 through various targeted mechanisms within cellular signaling pathways. Indirubin and flavopiridol, by serving as inhibitors of cyclin-dependent kinases, reduce the phosphorylation of competitive substrates, thus indirectly enhancing CLK3-mediated phosphorylation. This is complemented by harmine's inhibition of DYRKs, which augments the phosphorylation potential of CLK3 on its specific substrates. Similarly, TG003, although a CLK3 inhibitor, at sub-inhibitory concentrations prompts a cellular compensatory reaction that can bolster CLK3 activity, essential for splicing functions. 5-Iodotubercidin and cycloheximide indirectly upregulate CLK3 by increasing ATP availability and stabilizing CLK3 protein levels, respectively, thus amplifying its kinase activity. The interplay between CLK3 and other kinases is further exemplified by D4476 and IC261, which inhibit CK1, leading to an enhancement of CLK3 signaling by mitigating CK1's suppressive phosphorylation effects.
The specificity of these activators in influencing CLK3's role is underscored by their individual modes of action that converge on the enhancement of CLK3. Kenpaullone's inhibition of GSK3 potentially frees CLK3 from a phosphorylation-based inhibition, enabling it to more effectively fulfill its role in the phosphorylation cascades. The selective inhibition of competing kinases by 1-NM-PP1 and roscovitine further clears the path for CLK3's substrates to be phosphorylated without interference, thereby facilitating CLK3's functional activity. DRB's reduction in phosphorylation of RNA Polymerase II regulatory proteins indirectly promotes CLK3's involvement in the modulation of alternative splicing events. Collectively, these chemical compounds, through their targeted modulation of cellular kinases and substrates, create an environment that is conducive to the enhanced activity of CLK3, demonstrating a broad yet interconnected spectrum of indirect activation mechanisms.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indirubin | 479-41-4 | sc-201531 sc-201531A | 5 mg 25 mg | $114.00 $525.00 | 4 | |
Indirubin, an inhibitor of cyclin-dependent kinases (CDKs), can enhance CLK3 activity by inhibiting competing kinases that phosphorylate the same substrates, thereby reducing substrate competition and indirectly increasing CLK3-mediated phosphorylation events. | ||||||
Harmine | 442-51-3 | sc-202644 sc-202644A sc-202644B sc-202644C sc-202644D sc-202644E sc-202644F | 250 mg 500 mg 1 g 10 g 50 g 100 g 500 g | $53.00 $104.00 $126.00 $551.00 $1467.00 $2611.00 $11455.00 | 2 | |
Harmine acts as a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor. By inhibiting DYRKs, it can upregulate substrates of CLK3, thereby indirectly enhancing CLK3's functional activity within its specific signaling pathways. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that can indirectly enhance CLK3 by increasing the availability of adenosine triphosphate (ATP), which is required for CLK3 kinase activity. Increased ATP levels can thus lead to an increase in CLK3's phosphorylation capacity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a CDK inhibitor, can indirectly enhance CLK3 activity by inhibiting CDKs that otherwise phosphorylate substrates or regulatory proteins that would inhibit CLK3 function, thereby reducing negative regulation on CLK3 activity. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $99.00 | 6 | |
D4476 is known as a casein kinase 1 (CK1) inhibitor. By inhibiting CK1, it can enhance CLK3's activity by preventing CK1-mediated phosphorylation of proteins that would normally suppress CLK3's kinase activity, thereby indirectly upregulating CLK3's function. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB acts as an inhibitor of CDK9 and can enhance CLK3 by reducing phosphorylation of proteins involved in RNA Polymerase II regulation, which in turn can modulate alternative splicing events where CLK3 is a key player. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is a potent inhibitor of glycogen synthase kinase 3 (GSK3). By inhibiting GSK3, it may enhance CLK3 activity due to the interplay between GSK3 and CLK3 in phosphorylation cascades, allowing CLK3 to phosphorylate its substrates more effectively. | ||||||
1-Naphthyl PP1 | 221243-82-9 | sc-203765 sc-203765A | 10 mg 50 mg | $235.00 $983.00 | 3 | |
1-NM-PP1 is an analog of staurosporine that acts as a kinase inhibitor. When targeted against other kinases, it can indirectly enhance CLK3 activity by reducing competitive phosphorylation of CLK3's substrates. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor. By inhibiting general protein synthesis, it can lead to the stabilization of CLK3 protein levels by preventing the synthesis of regulatory proteins that might degrade or inhibit CLK3, thus potentially enhancing its activity. | ||||||
IC261 | 186611-52-9 | sc-3561 | 5 mg | $140.00 | 11 | |
IC261 is a selective inhibitor of CK1. Inhibition of CK1 can increase the functional activity of CLK3 by reducing the phosphorylation of competing substrates or by altering the regulatory proteins that control CLK3's kinase activity, thus indirectly enhancing CLK3 signaling. | ||||||